Citation

Narang P, Madigan K, Sarai S, Lippmann S. Innov. Clin. Neurosci. 2019; 16(9-10): 33-35.

Copyright

(Copyright © 2019, Matrix Medical Communications)

DOI

unavailable

PMID

unavailable

Abstract

Children who are inadequately treated for depression often experience greater dysfunction. Problems can include conduct disorders, substance abuse, physical illness, and poor performance at school, work, or in psychosocial contexts. Depression can lead to a greater risk of suicide. Suicide is the third most common cause of death among adolescents, with more than 500,000 attempts made by children each year. Suicide is the third most frequent cause of death among young people ages 10 to 19 years old. Thus, proper treatment is important. Major depressive disorder in adolescents is often followed by frequent recurrences in adulthood. Imaging studies document underactivity in the left dorsolateral prefrontal cortex in subjects suffering from depression. Activation of the brain with high-frequency transcranial magnetic stimulation increases neuronal excitability and induces the growth of new connections. Though larger, randomized, controlled trials with more patients and longer follow-up are needed, the favorable side effect profile and efficacy of TMS seen so far in the literature support the use of TMS as a therapeutic intervention in children and adolescents with depression. © 2019, Matrix Medical Communications. All rights reserved.

Language: en

Keywords

adolescent; human; cognition; Depression; suicide; psychotherapy; depression; major depression; Transcranial magnetic stimulation; disease severity; Neurostimulation; epilepsy; mental disease; antidepressant agent; serotonin uptake inhibitor; headache; neurotransmission; psychopharmacotherapy; seizure; valproic acid; neurologic disease; magnetic field; remission; 4 aminobutyric acid; GABAergic system; electroencephalography; Adolescent depression; transcranial magnetic stimulation; Article; motor cortex; hearing impairment; nerve excitability; myelination; dorsolateral prefrontal cortex; Affective illness; motor evoked potential